Life Science Leaders Weigh In On Build Back Better Provisions

On Friday, November 19, 2021, the U.S. House of Representatives passed the Build Back Better bill on a 220-213 vote.  The bill now moves to the Senate for further review and action. Valued at close to $2 trillion, the bill includes  a potpourri of  Democratic social spending priorities that includes free preschool for 3 and 4 year old children, initiatives to fight climate change and affordable housing programs. The bill also includes increases to  Pell grants for college tuition, expands family leave, and provides new hearing benefit for seniors.   It also incudes “pay fors” including   increases corporate taxes, funds additional resources for IRS enforcement, AND implements price controls on certain medicines.  Investors and life science companies of all sizes have expressed serious concerns that if the latter provisions pass the Senate and are implemented the impact on future health innovation could be devastating. Continue reading

Arizona’s Launch of the NAM Pharma Manufacturing Report

Learn about the biopharmaceutical industry’s footprint in the state of Arizona as we discuss the National Association of Manufacturers’ report:

Ensuring a Health Future: The Impact and Importance of Pharmaceutical Manufacturing.




Shawn DuBravac, PhD, CFA, President, Aviro Institute and New York Times Best Selling Author

Garrick Taylor, EVP, Arizona Chamber of Commerce & Industry

Moderator: Joan Koerber-Walker, president & CEO, Arizona Bioindustry Association (AZBio)

Clouds Over the Capitol

TRIPS Waiver, MCIT, HR3.  If you are not familiar with these policy developments, you probably should be.

The United States medtech and biotech industries make a tremendous impact on people’s lives.   When policy makers and Federal Agencies work together, the impact is made even greater.  However, some policy decisions can have the opposite effect.

Continue reading

BIO Leads Group Challenging Administration’s “Most Favored Nation” Rule

On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading